Intervention

ladiratuzumab vedotin

ClinicalTrials.gov intervention label

Clinical trials3

Recruiting0

Common conditions13

Lead sponsors shown1

Clinical trials

3 shown

A Study of Ladiratuzumab Vedotin in Advanced Solid TumorsNCT04032704 · 2019-10-09

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast CancerNCT03310957 · 2018-02-27

A Safety Study of SGN-LIV1A in Breast Cancer PatientsNCT01969643 · 2013-10-22

Common conditions

Triple Negative Breast Neoplasms2 Esophageal Squamous Cell Carcinoma1 Gastric Adenocarcinoma1 Gastroesophageal Junction Adenocarcinoma1 Head and Neck Squamous Cell Carcinoma1 HER2 Mutations Breast Neoplasms1 HER2 Positive Breast Neoplasms1 Hormone Receptor Positive Breast Neoplasms1 Melanoma1 Non-small Cell Lung Cancer, Non-squamous1 Non-small Cell Lung Cancer, Squamous1 Prostate Cancer1 Small Cell Lung Cancer1

Leading sponsors

Trial status mix

COMPLETED2

TERMINATED1

Phase mix

PHASE12

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.